UCB SA (OTCMKTS:UCBJY) Sees Significant Decline in Short Interest

UCB SA (OTCMKTS:UCBJY) was the target of a significant decline in short interest during the month of December. As of December 15th, there was short interest totalling 200 shares, a decline of 80.0% from the November 30th total of 1,000 shares. Based on an average daily volume of 11,900 shares, the short-interest ratio is currently 0.0 days.

UCB Price Performance

UCB stock opened at $100.40 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The firm has a fifty day simple moving average of $96.05 and a two-hundred day simple moving average of $88.41. UCB has a twelve month low of $43.17 and a twelve month high of $100.43.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.